AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26808585 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 15245
Study 26808585 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset diabetic patients
Number of subjects: 15245
Study 26808585 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 15245
Study 26631161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 26631161 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training
Number of subjects: 60
Study 26631161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive intervention (ACoTrain)
Number of subjects: 60
Study 26631161 — intervention group
Group type: COMPARATOR
Intervention: Control group (individual rehabilitation programme)
Number of subjects: 60
Study 23731073 — intervention group
Group type: COMPARATOR
Intervention: Devaluation of UCS (decreased intensity after acquisition)
Number of subjects: 0
Study 23731073 — intervention group
Group type: COMPARATOR
Intervention: Inflation of UCS (increased intensity after acquisition)
Number of subjects: 0
Study 20613542 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen (group A)
Number of subjects: 53
Study 18853696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake with RDI >= 50
Number of subjects: 320
Study 18853696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake among women with RDI >= 50
Number of subjects: 320
Study 18853696 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric expenditure with RDI >= 50
Number of subjects: 320
Study 16321825 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 23
Study 16321825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 12801944 — intervention group
Group type: EXPERIMENTAL
Intervention: Flamingo covered Wallstent
Number of subjects: 53
Study 12801944 — intervention group
Group type: COMPARATOR
Intervention: Ultraflex covered stent
Number of subjects: 53
Study 11011342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus Rhythm (SR)
Number of subjects: 583
Study 11011342 — intervention group
Group type: COMPARATOR
Intervention: Atrial Fibrillation (AF)
Number of subjects: 583
Study 8798372 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective nonoperative management
Number of subjects: 51
Study 8798372 — intervention group
Group type: COMPARATOR
Intervention: Mandatory laparotomy
Number of subjects: 51
Study 1623901 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 6-mercaptopurine (30 mg/m2)
Number of subjects: 5
Study 1623901 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 6-mercaptopurine (87.5 mg/m2)
Number of subjects: 5
Study 1623901 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 6-mercaptopurine
Number of subjects: 5
Study 6363955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate (B)
Number of subjects: 23
Study 30864472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential IPC for 10 minutes
Number of subjects: 20
Study 30864472 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-compartment IPC for 10 minutes
Number of subjects: 20
Study 30864472 — intervention group
Group type: COMPARATOR
Intervention: Sequential IPC compared to Single-compartment IPC
Number of subjects: 20
Study 27650094 — intervention group
Group type: EXPERIMENTAL
Intervention: Heyan Kuntai Capsule (HYKT)
Number of subjects: 390
Study 27650094 — intervention group
Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 390
Study 26484951 — intervention group
Group type: COMPARATOR
Intervention: Lower extremity venous occlusion at 100 mm Hg
Number of subjects: 19
Study 26484951 — intervention group
Group type: COMPARATOR
Intervention: Lower extremity venous occlusion
Number of subjects: 19
Study 24690625 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri DSM 17938 (1 × 10(8) colony forming units)
Number of subjects: 167
Study 24690625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 22747846 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! intervention
Number of subjects: 1583
Study 21050239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 treatment
Number of subjects: 20
Study 21050239 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 17147966 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-learning group (n = 65)
Number of subjects: 130
Study 17147966 — intervention group
Group type: COMPARATOR
Intervention: Solo-learning control group (n = 65)
Number of subjects: 130
Study 15172083 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise three‐times weekly over 12 weeks
Number of subjects: 75
Study 15172083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol therapy for 12 weeks
Number of subjects: 75
Study 12352236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 percent nitroglycerin ointment applied twice or three times per day
Number of subjects: 304
Study 12352236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 304
Study 9519417 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott IMx assay
Number of subjects: 85
Study 9519417 — intervention group
Group type: COMPARATOR
Intervention: Hybritech Tandem‐E assay
Number of subjects: 85
Study 9815340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 1741
Study 9815340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine with domperidone
Number of subjects: 1741
Study 9815340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine
Number of subjects: 1741
Study 9815340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate with caffeine
Number of subjects: 1741
Study 9815340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root
Number of subjects: 1741
Study 9815340 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclozine with caffeine
Number of subjects: 1741
Study 9815340 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine Transdermal Therapeutic System (TTS)
Number of subjects: 1741
Study 2643969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram alphacalcidol (1 alpha‐hydroxy‐vitamin D3)
Number of subjects: 39
Study 2643969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29538686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554
Study 29538686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study 28817301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient financial incentives
Number of subjects: 30
Study 28817301 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions with financial incentives
Number of subjects: 30
Study 28817301 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence monitoring and financial incentives
Number of subjects: 30
Study 26643558 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antenatal and postnatal home-based care plus screening and treatment for abnormal vaginal flora (AVF) and urinary tract infection (UTI).
Number of subjects: 10000
Study 26643558 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal and postnatal home-based care (control arm).
Number of subjects: 10000
Study 24267622 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal reflective blanket
Number of subjects: 58
Study 24267622 — intervention group
Group type: COMPARATOR
Intervention: No thermal reflective blanket (Control)
Number of subjects: 58
Study 21105759 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring (HBPM)
Number of subjects: 223
Study 21105759 — intervention group
Group type: COMPARATOR
Intervention: Conventional office BP monitoring
Number of subjects: 223
Study 18637554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroid (diluted Triamcinolone acetonide)
Number of subjects: 24
Study 18637554 — intervention group
Group type: COMPARATOR
Intervention: Silicone-gel sheeting
Number of subjects: 24
Study 16125146 — intervention group
Group type: EXPERIMENTAL
Intervention: STin2 10 allele presence
Number of subjects: 258
Study 16125146 — intervention group
Group type: EXPERIMENTAL
Intervention: STin2 variant with family history of suicide
Number of subjects: 258
Study 12660407 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose (10 g/d for 5 d)
Number of subjects: 19
Study 12660407 — intervention group
Group type: COMPARATOR
Intervention: Dextrose placebo (5 g, twice daily)
Number of subjects: 19
Study 10773058 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs collected from unrelated donors
Number of subjects: 40
Study 10773058 — intervention group
Group type: COMPARATOR
Intervention: RBCs collected from biologic parents
Number of subjects: 40
Study 8629917 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview using the Functional Independence Measure (FIM)
Number of subjects: 40
Study 8629917 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment using the Functional Independence Measure (FIM)
Number of subjects: 40
Study 1279292 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril
Number of subjects: 22
Study 1279292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg cilazapril + 0.5 mg cyclopenthiazide (CPTZ)
Number of subjects: 22
Study 1279292 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril + 0.5 mg CPTZ
Number of subjects: 22
Study 1279292 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril alone
Number of subjects: 22
Study 1279292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2988158 — intervention group
Group type: EXPERIMENTAL
Intervention: suloctidil (200 mg t.i.d.)
Number of subjects: 438
Study 2988158 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 438
Study 30453329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive‐communication rehabilitation (ICCR) program
Number of subjects: 4
Study 30453329 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4
Study 28982479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led decision coaching sessions, access to DECIMS-Wiki, final physician consultation
Number of subjects: 73
Study 28982479 — intervention group
Group type: COMPARATOR
Intervention: Care as usual with access to DECIMS-Wiki
Number of subjects: 73
Study 26720704 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TDCS (2 mA, 20 min)
Number of subjects: 37
Study 26720704 — intervention group
Group type: COMPARATOR
Intervention: Sham TDCS
Number of subjects: 37
Study 24670612 — intervention group
Group type: COMPARATOR
Intervention: Affected side GPS
Number of subjects: 47
Study 24670612 — intervention group
Group type: COMPARATOR
Intervention: Unaffected side GPS
Number of subjects: 47
Study 24670612 — intervention group
Group type: COMPARATOR
Intervention: Control group GPS
Number of subjects: 47
Study 24670612 — intervention group
Group type: COMPARATOR
Intervention: Affected side APS
Number of subjects: 47
Study 24670612 — intervention group
Group type: COMPARATOR
Intervention: Unaffected side APS
Number of subjects: 47
Study 24670612 — intervention group
Group type: COMPARATOR
Intervention: Control group APS
Number of subjects: 47
Study 24670612 — intervention group
Group type: COMPARATOR
Intervention: Lower extremity asymmetry
Number of subjects: 47
Study 22083263 — intervention group
Group type: EXPERIMENTAL
Intervention: Right half‐field patch treatment (n=10) for approximately 8 hours a day for 15 consecutive days
Number of subjects: 18
Study 22083263 — intervention group
Group type: COMPARATOR
Intervention: Visual scanning training (n=8) for 40 minutes every weekday in a 15 day period
Number of subjects: 18
Study 20395128 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 7 every 3 weeks followed by concurrent paclitaxel 175 mg/m2 (day 1) and gemcitabine 1000 mg/m2 (days 1 and 8) every 3 weeks
Number of subjects: 54
Study 20395128 — intervention group
Group type: COMPARATOR
Intervention: Sequential schedule with weekly paclitaxel
Number of subjects: 54
Study 18238836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax‐AWS
Number of subjects: 203
Study 18238836 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 203
Study 16037481 — intervention group
Group type: EXPERIMENTAL
Intervention: Programa de Entrenamiento para el Desarrollo de Aptitudes para Latinos (PEDAL) group therapy
Number of subjects: 29
Study 16037481 — intervention group
Group type: COMPARATOR
Intervention: Support group (SG)
Number of subjects: 29
Study 12406527 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 12406527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham-EA
Number of subjects: 100
Study 12406527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-EA
Number of subjects: 100
Study 12406527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-EA
Number of subjects: 100
Study 10567776 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH, 300 mg once daily) plus sulphadoxine-pyrimethamine (S, 500 mg/P, 25 mg once weekly)
Number of subjects: 263
Study 10567776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 263
Study 7762496 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches
Number of subjects: 18
Study 7762496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1692533 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium glycerophosphate
Number of subjects: 11
Study 428710 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA), 750 mg/day during weight maintenance (1st month) and weight reduction (2nd month)
Number of subjects: 24
Study 428710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acid preparations (CDCA and Bilron) administered randomly during weight reduction
Number of subjects: 24
Study 428710 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight maintenance with no bile acid feeding)
Number of subjects: 24
Study 31623899 — intervention group
Group type: EXPERIMENTAL
Intervention: New models for estimating foetal weight (EFW) using MRI
Number of subjects: 153
Study 31623899 — intervention group
Group type: COMPARATOR
Intervention: Existing model developed by Baker et al.
Number of subjects: 153
Study 28801403 — intervention group
Group type: EXPERIMENTAL
Intervention: Two, 150 min, skills‐based training sessions focused on communication and behaviour change skills with between session practice.
Number of subjects: 12
Study 28801403 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 12
Study 25173772 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing without water (bed bath with disposable wash gloves)
Number of subjects: 500
Study 25173772 — intervention group
Group type: COMPARATOR
Intervention: Traditional bed bath (using soap, water, washcloths, and towels)
Number of subjects: 500
Study 25173772 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing without water
Number of subjects: 500
Study 25173772 — intervention group
Group type: COMPARATOR
Intervention: Traditional bed bath
Number of subjects: 500
Study 22464479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedural TIMI flow 0/1
Number of subjects: 3582
Study 22464479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedural TIMI flow 2
Number of subjects: 3582
Study 22464479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedural TIMI flow 3
Number of subjects: 3582
Study 22464479 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI 3 flow achievement
Number of subjects: 3582
Study 22111802 — intervention group
Group type: EXPERIMENTAL
Intervention: standard care therapy over seven-days a week
Number of subjects: 282
Study 22111802 — intervention group
Group type: EXPERIMENTAL
Intervention: group circuit class therapy over five-days a week
Number of subjects: 282
Study 22111802 — intervention group
Group type: COMPARATOR
Intervention: usual care therapy over five-days a week
Number of subjects: 282
Study 18154473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg every 12 hours for 4 days
Number of subjects: 20
Study 18154473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg every 12 hours and omeprazole 40 mg every 24 hours for 4 days
Number of subjects: 20
Study 18154473 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir alone
Number of subjects: 20
Study 18154473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir with omeprazole
Number of subjects: 20
Study 18074761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extracts Iscador (therapy suggested by attending physician)
Number of subjects: 198
Study 18074761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extracts Iscador (non-randomized studies)
Number of subjects: 198
Study 18074761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extracts Iscador (therapy)
Number of subjects: 198
Study 18074761 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (control)
Number of subjects: 198
Study 12895618 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 0
Study 12895618 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 0
Study 10703459 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) snacks
Number of subjects: 8
Study 10703459 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) snacks
Number of subjects: 8
Study 10703459 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF) snacks
Number of subjects: 8
Study 10703459 — intervention group
Group type: COMPARATOR
Intervention: No Snack (NS)
Number of subjects: 8
Study 10703459 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (HP, HC, HF, NS)
Number of subjects: 8
Study 9166037 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental questionnaire
Number of subjects: 88
Study 9166037 — intervention group
Group type: COMPARATOR
Intervention: Paediatric assessment
Number of subjects: 88
Study 1304181 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal matrix, large tip
Number of subjects: 80
Study 1304181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylar matrix, light emitting wedge, large tip
Number of subjects: 80
Study 1304181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylar matrix, light emitting wedge, small tip
Number of subjects: 80
Study 1304181 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal matrix, small tip
Number of subjects: 80
Study 1304181 — intervention group
Group type: COMPARATOR
Intervention: Dentin gingival cavosurface margin groups
Number of subjects: 80
Study 1304181 — intervention group
Group type: COMPARATOR
Intervention: Metal matrix groups
Number of subjects: 80
Study 2580155 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (cumulative doses of 1-8 mg)
Number of subjects: 0
Study 2580155 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (cumulative doses of 10-80 mg)
Number of subjects: 0
Study 27958381 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 582
Study 27958381 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/naloxone (Suboxone) treatment
Number of subjects: 582
Study 27958381 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype at rs10485058
Number of subjects: 582
Study 27956680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (n=40, Rop group)
Number of subjects: 80
Study 27956680 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n=40, NS group)
Number of subjects: 80
Study 27956680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (Rop group)
Number of subjects: 80
Study 27956680 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS group)
Number of subjects: 80
Study 24733277 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention for depression and anxiety disorders (n=92)
Number of subjects: 183
Study 24733277 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group, n=91)
Number of subjects: 183
Study 24733277 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 183
Study 24733277 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 183
Study 22445052 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy intervention
Number of subjects: 100
Study 20955499 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 840
Study 20955499 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected infants
Number of subjects: 840
Study 18612787 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD‐FP (5‐FU, 320 mg/m² daily for 21 days; CDDP, 3.5 mg/m² daily for 21 days) followed by oral 5‐FU (200 mg/body daily for 2 years)
Number of subjects: 188
Study 18612787 — intervention group
Group type: COMPARATOR
Intervention: Oral 5‐FU therapy (200 mg/body daily for 2 years)
Number of subjects: 188
Study 16026402 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical abortion
Number of subjects: 368
Study 16026402 — intervention group
Group type: COMPARATOR
Intervention: Medical abortion
Number of subjects: 368
Study 12052597 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (100 microg every 3-4 hours, with possible increase to 200 microg)
Number of subjects: 107
Study 12052597 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (25 microg every 3-4 hours, with possible increase to 50 microg)
Number of subjects: 107
Study 10672723 — intervention group
Group type: EXPERIMENTAL
Intervention: Amizon (anti-inflammatory interferon-inducing drug)
Number of subjects: 265
Study 10672723 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 265
Study 8754965 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids (prednisone)
Number of subjects: 80
Study 8754965 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids in typical dose
Number of subjects: 80
Study 8754965 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers of bone turnover
Number of subjects: 80